EBRO 2017

Conclusions

Most studies suggest there is no increased risk of breast recurrence in BRCA 1/2 carriers at 10 years and longer follow-up

Age is the strongest predictor of local recurrence

Added benefit from tamoxifen and / or oophorectomy

Added benefit from chemotherapy

New targeted treatments could change the prognosis of these cancers